Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs.

Building on the earlier partnership announced in October 2021 to commercialize tab-cel in Europe, this transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets.

With the closing of the transaction, Atara will receive approximately $ 27 million in cash upfront and initial inventory purchase. Under the agreement, Atara has the potential to receive up to a total of $ 640 million and significant double-digit tiered royalties on net sales, including up to $ 100 million in potential regulatory milestones through BLA approval. In addition, Pierre Fabre Laboratories will reimburse Atara for expected tab-cel global development costs through the Biologics License Application (BLA) transfer, and purchase future tab-cel inventory through the manufacturing transfer date.

Ebvallo is EU approved for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).